Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy

Breast Cancer Research and Treatment

Volumn 85, Issue 3, 2004, Pages 211-218

  Bodini, Maria ^a   Berruti, Alfredo ^b   Bottini, Alberto ^a   Allevi, Giovanni ^a   Fiorentino, Carla ^a   Brizzi, Maria Pia ^b   Bersiga, Alessandra ^a   Generali, Daniele ^a   Volpi, Davide ^a   Marini, Ugo ^a   Aguggini, Sergio ^a   Tampellini, Marco ^b   Alquati, Palmiro ^a   Olivetti, Lucio ^a   Dogliotti, Luigi ^b,c  

^a Ist Osp   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Breast cancer; Clinical palpation; Magnetic resonance imaging; Primary chemotherapy

Indexed keywords

EPIRUBICIN; GADOLINIUM PENTETATE; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CARCINOMA IN SITU; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PRIORITY JOURNAL; BREAST TUMOR; COMPARATIVE STUDY; DRUG MONITORING; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NONPARAMETRIC TEST; PATHOLOGY; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DRUG MONITORING; EPIRUBICIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM, RESIDUAL; PALPATION; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 3042671973     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000025409.69516.23     Document Type: Article

References (28)

1. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Y, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimetres and more. J Natl Cancer Inst 82: 1539-1545, 1990
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
3. Mamounas EP, Fisher B: Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 28: 389-399, 2001
4. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Molinterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight years experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998
5. Fisher B, Mamounas EP: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537-540, 1995
6. Aapro M: Neoadjuvant therapy in breast cancer: can we define its role? Oncologist 6(Suppl 3): 36-39, 2001
7. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L: p53 but not bc12 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000
8. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L: Relationship between tumor shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85: 1106-1112, 2001
9. Cocconi G, DiBlasio B, Alberti G, Bisagni G, Botti E, Peracchia G: Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4: 309-313, 1984
10. Jockelson M: Breast cancer imaging: the future. Semin Oncol 28: 221-228, 2001
11. Nistrom L: Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet 341: 973-978, 1993
12. Fiorentino C, Berruti A, Bottini A, Bodini M, Brizzi MP, Brunelli A, Marini U, Allevi G, Aguggini S, Tira A, Alquati P, Olivetti L, Dogliotti L: Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 69: 143-151, 2001
13. Trecate G, Tess JD, Vergnaghi D, Bergonzi S, De Simone T, Mariani G, Musumeci R: Breast microcalcifications studied with 3D contrast enhanced high-field magnetic resonance imaging: more accuracy in the diagnosis of breast cancer. Tumori 88: 224-233, 2002
14. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, Laheij RJ, Massuger L, van Die LE, Wobbes T, Barentsz JO: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93: 1095-1102, 2001
15. Khatri VP, Stuppino JJ, Espinosa MH, Pollack MS: Improved accuracy in differentiating malignant from benign mammographic abnormalities. Cancer 92: 471-178, 2001
16. Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE: Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign lesions. Breast Cancer Res Treat 45: 39-46, 1997
17. Miller AB, Hoogstroten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
18. Gilles R, Guinebretière JM, Troussaint C, Spielman M, Rietjens M, Petit JY, Contesso G, Masselot J, Vanel D: Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology, 191: 633-638, 1994
19. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91-100, 1996
20. Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, Tomczak R: MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70: 234-239, 1997
21. Trecate G, Ceglia E, Stabile F, Tesoro-Tess JD, Mariani G, Zambetti M, Musumeci R: Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease. Tumori 85: 220-228, 1999
22. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuere H, Sudilovsky D, Lu Y, Hylton N: MRI phenotype is associated with response to doxombicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8: 549-559, 2001
23. Weatherall PT, Evans GF, Metzger G, Saborrian MH, Leitch AM: MRI vs histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 13: 868-875, 2001
24. Davis PL, Staiger MJ, Harris KB, Ganott MA, Klementaviciene I, McCarty Jr KS, Tobon H: Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 37: 1-9, 1996
25. Kinkel K, Hylton NM: Challenges to interpretation of breast MRI. J Magn Reson Imaging 13: 821-829, 2001
26. Esserman L, Wolverton D, Hylton N: Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocrine-Related Cancer 9: 141-153, 2002
27. Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM: MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MRI imaging. Am J Roentgenol 175: 1577-1584, 2000
28. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB: Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43: 500-509, 2002